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ABSTRACT
With the introduction of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative 
chronic kidney disease (CKD) guidelines, CKD has been identified as common, particularly in the 
elderly. The outcomes for those with CKD can be poor: mortality, initiation of renal replacement therapy, 
and progressive deterioration in kidney function, with its associated complications. In young people 
with CKD, the risk of poor outcome is high and the social cost substantial, but the actual number of 
patients affected is relatively small. In the elderly, the risk of poor outcome is substantially lower, but 
due to the high prevalence of CKD the actual number of poor outcomes attributable to CKD is higher. 
Predicting which patients are at greatest risk, and being able to tailor care appropriately, has significant 
potential benefits. Risk prediction models in CKD are being developed and show promise but thus far have 
limitations. In this review we describe the pathway for developing and evaluating risk prediction tools, and 
consider what models we have for CKD prediction and where next.
Keywords: Chronic kidney disease, outcome, risk prediction.  
CHRONIC KIDNEY DISEASE: THE 
BURDEN OF CARE
The recognition of chronic kidney disease (CKD) 
prior to 2002  was inconsistent, with no standard 
definition and, in some cases, led to late referral 
of patients to specialised renal services.1,2 This 
was associated with poor outcomes on renal 
replacement therapy (RRT)1-3 and missed clinical 
opportunity to improve disease course.1 The 
introduction of the National Kidney Foundation 
Kidney Disease Outcomes Quality Initiative 
(KDOQI) CKD definitions,4 international acceptance 
of these definitions, and instigation of CKD 
guidelines5-9 has led to a recognition that the 
prevalence and incidence of CKD is far in excess of 
earlier estimates.10-12 Reports based on data from 
the National Health and Nutrition Examination 
Survey (NHANES) suggested 13.1% (26 million) of 
the US adult population in 2000 had CKD.13 The 
prevalence of CKD increases with age; in NHANES 
approximately 50% of those aged 70 years and 
older were reported to have CKD.13 This is set to 
grow as the global population ages.14 A recent study 
estimated that the lifetime risk of developing CKD 
Stage 3-5 was approximately 60%; three out of five 
babies born today are destined to develop CKD in 
their lifetime.15
The natural history of CKD is perceived to be one 
of loss of renal function over time with associated 
complications, leading ultimately to the need for 
RRT and finally death. With declining estimated 
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glomerular filtration rate  (eGFR) the risk of reaching 
end-stage renal disease (ESRD) increases, 
estimates vary. A Chronic Kidney Disease Prognosis 
Consortium (CKD-PC) patient-level meta-analysis 
reported increasing hazard ratios (HRs) with 
declining eGFR up to an adjusted ESRD HR of 51 
(32-83) 95% confidence interval (CI) for eGFR<15 
(versus 45-74 ml/min/1.73 m2).16 Worsening 
proteinuria is also associated with increasing risk 
of ESRD; CKD-PC report a HR of 9 (2-50) for ACR 
≥1000 (versus <30) mg/g.16 All-cause mortality also 
increased with worsening eGFR and worsening 
proteinuria.17 Other outcomes for those with CKD 
include a high cardiovascular morbidity and 
mortality.18 Progressive deterioration in kidney 
function, short of the requirement for RRT, carries 
the risk of developing anaemia, acidosis, bone 
disease, a need to prepare for RRT, or instigation 
of conservative care. Recent CKD cohort reports 
confirm that, although many initiate RRT or die, a 
significant number may still be alive after several 
years. Our own data on Stage 3b-5 CKD suggest 
that approximately one-third are still alive and not 
requiring RRT at 5 years.19
CKD and the associated increased use of hospital 
services20 come with a significant financial 
cost – estimated for England’s NHS during 2009-10 
to be at £1.45 billion (~1.3% of NHS spending), of 
which just over half was due to RRT costs.21 
Instigation of RRT also involves other costs; these 
include personal loss of earnings, health, and 
personal-social costs both for patients and their 
carers. Thus, in the general population there is a 
high burden of CKD both in terms of volume of 
disease and cost of treatment and management.
INDIVIDUAL RISK VERSUS POPULATION
BURDEN: AGE MATTERS
The burden from CKD is high, but the risk is 
not constant for all patients, and age is a major 
influence on risk and outcome. In the young, 
the risk of poor outcome is high in those with 
CKD compared to those of similar age without 
CKD. The actual numbers of patients affected 
is, however, relatively small because CKD prevalence 
is low and the outcomes are uncommon in the 
‘unexposed’ non-CKD population. In the elderly, 
the relative risk of poor outcome is substantially 
lower as compared to those of similar age without 
CKD, but due to the high prevalence of CKD the 
actual number of poor outcomes attributable to 
CKD is high.19
The effect of this difference in risk is illustrated 
in Figure 1. Relative risk defines the strength of 
the association between the outcome and the 
exposure (in this case CKD and RRT or death). 
Absolute measures of risk estimate the impact of 
a disease (here, CKD) on an individual, or indeed 
population. For an individual this would be the 
difference in risk of a given outcome depending 
on whether a person has the disease (CKD) or not 
– the excess risk associated with having CKD.22 
For populations, the population attributable 
risk describes how much of an outcome can be 
accounted for by exposure to a particular disease 
in the population, and therefore takes into account 
the disease prevalence.22
Figure 1a illustrates the prevalence of CKD for a 
population. The mortality in those without and 
with CKD are illustrated in Figure 1b; this uses 
figures from the CKD-PC meta-analysis reported 
by Hallan et al.23 using the mean mortality rates 
for those with eGFRs of 80 and 45 ml/min/1.73 
m2, respectively to represent an average individual 
with ‘no CKD’ and ‘CKD’, respectively. For those 
aged 18-54 years the mean mortality rates were 
4.0 and 13.0 per 1000 patient-years (py) for 
‘no CKD’ and ‘CKD’ individuals, respectively, thus, 
individuals with CKD had an excess mortality risk 
of 9 per 1000 py, and a mortality HR or relative risk 
of ~3 as a result of CKD. Given that the prevalence 
of CKD is low in those aged 18-54, this excess 
personal risk translates into a relatively small 
excess number of deaths (the numbers shown in 
Figure 1d are purely illustrative since they are 
estimated using outcomes for those with an eGFR 
of 45 ml/min/1.73 m2 to represent those with CKD, 
whereas the majority of those with CKD will have a 
far better eGFR than this). As shown in Figure 1b, 
for those aged ≥75 years, mean mortality rates for 
‘no CKD’ and ‘CKD’ were 57.8 and 85.0 per 1,000 
py, an excess individual risk of 27.2 per 1,000 py and 
a much lower relative risk of  ~1.3. However, as 
illustrated in Figure 1d the far higher prevalence of 
CKD means that the excess deaths are far higher 
despite this lower relative risk. 
The equivalent mean rates for achieving ESRD 
reported by Hallan et al.23 in those with ‘no CKD’ 
and ‘CKD’ (eGFRs of 80 and 45 ml/min/1.73 m2, 
respectively) by age are shown in Figure 1c. The 
rates were higher in the youngest groups, the 
relative risk was higher in the young also. The excess 
individual risks were 45.1 and 8.0 per 1,000 py for 
the youngest and oldest group, respectively. 
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However, since the numbers at risk are so small 
in the young, and large in the elderly, the excess 
cases of ESRD in the illustration are actually a 
little higher for those over 65 years of age. Thus, 
amongst the population there are two distinct 
groups – a group where CKD is uncommon but, 
for those with CKD the personal risk of poor 
outcomes are high, and a group where CKD is 
common but personal risk of poor outcomes is low. 
However, as a result of the number of individuals 
in this second group, they contribute a significant 
number of poor outcomes.
 For care planning, although in terms of personal risk 
there are certain groups at high-risk, the majority 
of those that actually contribute to the highest 
volume of care requirements are generally older 
and have a lower personal risk. Although to have 
a specialist review of the younger high-risk group 
is not challenging, identifying those at risk in the 
low relative-risk elderly group might be, but it is 
important for care-planning. An ability to accurately 
determine which of the high volume group with low 
personal risk are at more risk than their peers would 
allow directed care for RRT planning, pre-dialysis 
care, specialist nephrology input, and mortality 
risk reduction steps. Also, very importantly, it 
would identify those who will not suffer these poor 
outcomes, for whom nephrology care is unlikely 
to be necessary. In other medical fields with high 
volume disease, such as ischaemic heart disease,25,26 
prediction models for the assessment of risk 
have been introduced and are commonly used in 
clinical practice.
CKD OUTCOME PREDICTION AND CARE 
PATHWAY DEVELOPMENT
Developing safe and effective prediction models 
takes time and is a complex process.27-32 Models 
are developed using previous experience and work 
of others to inform and check likely prognosis and 
prognostic variables in a development cohort. 
Regression models are often then used to relate 
these variables and the outcome; importantly, 
indices of model performance are measured to 
decide on the ‘best’ model. A description of how 
well the model performs demonstrates internal 
validity. To demonstrate that the model performs 
well in another similar situation, external validation 
in another population is needed. Once good 
performance has been demonstrated, ideally 
a randomised controlled trial (with economic 
evaluation) would be used to demonstrate the 
implications of introducing the model into clinical 
practice. Then finally, if the model improved care 
or outcomes and had acceptable utility, it would be 
implemented in clinical practice. However, many of 
these steps are often not done and many developed 
models remain untested in clinical practice. 
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Figure 1: Population chronic kidney disease (CKD) prevalence, personal risk, relative risk, and population 
attributable risk. 
1a shows the prevalence of CKD in an illustrative adult population (based on unpublished data from 
Grampian Laboratory Outcomes Morbidity and Mortality 2 Study24); in the darker colour for both males and 
females are the number with an eGFR of <60 ml/min/1.73 m2, percentage values shown refer to the age-
bands as are demonstrated in b, c, d, and e. ** 1b, 1c, 1d, and 1e are based on rates published in Hallan et al.23 
with those with ‘not CKD’ and ‘CKD’ are based on figures for those with eGFR 80 and 45 ml/min/1.73 m2, 
respectively, although it should be kept in mind that the majority of those with CKD will have an eGFR>45 
so this will overestimate CKD excess risk dramatically, but it is used here for illustration purposes only and 
applied to the population in 1a. 1b shows in light grey the death rates by age for those with an eGFR of 80 
ml/min/1.73 m2 as representative of ‘Not CKD’, in dark grey is shown the additional risk in those with an 
eGFR of 45 ml/min/1.73 m2 as representing ‘CKD’, the * crude death rate ratio (based on the ratio of these 
two death rates) is shown in brackets. 1c shows similar for the occurrence of ESRD. 1d shows the excess 
number of deaths that could be expected in this population based on the difference between the death 
rates in those with and without CKD and the numbers with ‘CKD’ in the population. 1e shows the same for 
ESRD. Both are overestimates as the result of using the rates for 80 and 45 ml/min/1.73 m2 as estimates for 
those with ‘not CKD’ and ‘CKD’. 
In the field of renal medicine there are no prediction 
models for CKD outcomes that are in common use 
in clinical practice. But early work33 has been done 
that suggests prediction models could offer ways 
to plan and tailor care for people with CKD based 
on their risk of poor outcomes. Potential models 
have been developed to predict CKD outcome 
including mortality, cardiovascular disease, and 
kidney failure; the studies identified in two recent 
reviews34,35 are summarised in Table 1.
The identified prediction studies have shown that 
it is possible to develop models to predict outcome 
in those with CKD, using a wide range of data 
sources. The majority of these studies and models 
sought to predict ‘renal failure’ (most but not 
all defined by the initiation of RRT). Five of the 
identified studies report on models to predict 
mortality in those with CKD,34 sometimes as 
a composite end-point ‘death or renal failure’. 
Just three report cardiovascular event prediction 
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models, including a comparison with the 
performance of the Framingham risk equation. 
These death and cardiovascular models rarely 
report most performance metrics, except 
discrimination which were usually reasonable 
(C-statistics of 0.60 to 0.82).34
Of the ten studies developing prediction models 
for renal failure, two studies were in individuals 
with IgA nephropathy alone, and two in people with 
diabetic nephropathy, limiting generalisability for 
those with CKD of other or unknown cause. Only 
two studies were in community populations not 
identified through referral to specialist nephrology 
care. The variables in the models were important 
in terms of application to current clinical practice: 
those that are routinely performed such as 
creatinine (and eGFR) are easily translated into 
care; using variables that are only measured if 
clinically indicated potentially limits utility as does 
the use of biological measures that are not in 
common use in routine clinical practice such as 
cystatin C and NT-pro-BNP. No studies used the 
pattern or rate of eGFR or creatinine change as a 
predictor variable.
Study Setting, included 
individuals
Size Routine plus special 
measures
Stage in development
Dimitrov36 Clinic, RCT,
Nondiabetic CKD
344 Routine, calcium 
phosphate product
P. metrics (D+ C+)
Internal validation
Keane37 Clinic, RCT,
Diabetic 
nephropathy
1,513 Routine P. metrics (D- C-)
Internal validation
Wakai38 Clinic, cohort,
IgA nephropathy
2,269 Routine, BP, haematuria
Histological grade
P. metrics (D+ C-) 
Internal validation
Kent39 Clinic, RCTs,
Nondiabetic CKD
1,860 Routine, BP P. metrics (D+ C+) 
Internal validation
Johnson40 HMO cohort
CKD
9,782 Routine, BP, history of DM P. metrics (D+ C+) 
Internal validation
Goto41 Clinic, cohort,
IgA nephropathy 
only with eGFR 
>60 ml/min/1.73m2
790 Routine, BP, haematuria
Histological grade
P. metrics (D+ C+) 
Internal validation
Hallan42 Population,
cohort
CKD and no CKD
65,589 
(not all 
CKD)
Routine, BP, meds, DM, chol
Physical activity
P. metrics (D+ C-) 
Internal validation Explores 
potential clinical impact
Landray43 Clinic, cohort,
CKD
382 Routine, phosphate P. metrics (D+ C+) 
Internal validation, External 
validation (213)
Desai44 Clinic, RCT
Diabetics with 
CKD and anaemia
995 Routine, race, BMI, meds, Hx PAD/stroke/
HF/arrhythmia/AKI, ferritin, CRP
TnT, NT-pro-BNP
P. metrics (D+ C-) 
Internal validation
Tangri33 Clinic, cohort,
CKD
3,449 Routine, (8 variable model) phosphate, 
bicarbonate, calcium
P. metrics (D+ C+) 
Internal validation, External 
validation (4942)
Cardivascular events
Shlipak45 Population, cohort, 
CKD
1,249 Routine, race, education, meds, Hx of 
DM/ CVD, education, BP, BMI
P. metrics (D+ C-)
Weiner46 Population, cohort,
CKD
934 Routine, BP, chol, DM, smoking, race External validation of 
Framingham risk equation
P. metrics (D+ C+) of 
recalibrated model
McMurray47 Clinic, RCT,
Diabetics with 
CKD and anaemia
955 Routine, race, BMI, meds, Hx PAD/stroke/
HF/arrhythmia/ AKI, ferritin, CRP, ECG
TnT, NT-pro-BNP
P. metrics (D+ C-)
Table 1: Studies that report CKD outcome prediction models.
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Routine might include: age, sex, some creatinine based measure of excretory renal function, some 
measure of albuminuria, some measure of serum protein, some measure of anaemia; CKD: chronic kidney 
disease; ESRD: end-stage renal disease; RRT: renal replacement therapy; HMO: health maintenance 
organisation; RCT: randomised controlled trial; BP: blood pressure or hypertension; DM: diabetes 
mellitus; CVD: cardiovascular disease; Hx: history of; PAD: peripheral arterial disease; HF: heart failure; 
BMI: body mass index; AKI: acute kidney injury; CRP: C reactive protein; TnT: troponin T; NT-pro-BNP: 
N terminal prohormone brain natriuretic peptide. P. metrics: performance metrics; D+/D-: discrimination 
reported/not reported (usually as ROC or C statistic); C+/C-: calibration reported/not reported (usually 
as Hosmer-Lemeshow statistic or plot); Chol: cholesterol; ECG; electrocardiogram; BMI: body mass index.
Study Setting, included 
individuals
Size Routine plus special 
measures
Stage in development
All-cause mortality
Keane37 Clinic, RCT,
Diabetic 
nephropathy
1,513 Routine, HbA1c
All-cause mortality + ESRD
P. metrics (D- C-) 
Internal validation
Johnson48 HMO cohort,
CKD
6,541 Routine, BP, history of DM P. metrics (D+ C-) 
Landray43 Clinic, cohort,
CKD
382 Routine, smoking
NT-pro-BNP, TnT
P. metrics (D+ C+)
Internal validation External 
validation (213
Berthoux49 Clinic, cohort,
IgA nephropathy
332 Routine, BP
All-cause mortality + ESRD
Histological grade
P. metrics (D- C+)
Internal validation
Desai44 Diabetes type 2, 
CKD and anaemia
995 Routine, race, BMI, meds, Hx PAD/stroke/
HF/arrhythmia/AKI, ferritin, CRP
TnT, NT-pro-BNP
P. metrics (D+ C-) 
Internal validation
Reporting of the metrics considered of 
importance in the development of a prediction 
model (discrimination, calibration, model fit, 
and reclassification), summarised in Table 2 
and previously34,50 was variable. Discrimination 
was reported in the majority and was excellent; 
c-statistics of 0.79-0.94 (compared to the widely 
accepted Framingham model performance of 
0.75-0.81).25 Calibration was not consistently 
reported. The clinical implications were explored 
and reported in only one study,42 although model 
application to clinical care was discussed by 
two authors33,40 and useable interfaces presented 
by three.33,40,43 Only two authors demonstrated 
external validity.33,43 Both studies’ models were 
developed and externally validated in individuals 
referred to renal services and, as such, their 
performance in individuals from less specialised 
settings (e.g. community or non-specialist care) 
have not been demonstrated.33,43 
The best reported of these models were by Tangri 
et al.,33 who recounted model calibration, and for 
the several models developed report the relative 
performance of one model over another.33 The 
original study included external validation and 
they have since been externally validated by 
others.51 The performance of the Tangri 3 and 4 
variable models are illustrated in Figure 2 applying 
the models to an example CKD population cohort 
generated from our routine clinical practice in the 
North East of Scotland.19 The 3 variable model 
could be applied to the whole cohort; however, 
all 1,246 with Stage 4 CKD were labelled as 
high-risk when in fact only 89 had started RRT 
by 5 years (very sensitive, very poor specificity). 
Of the 4,951 with Stage 3b CKD (41 inititating RRT 
by 5 years) 2,053 were defined as high-risk 
(sensitivity 0.95, but specificity of only 0.59). The 
4 variable model restricted the number for whom 
there was appropriate data available as part of 
routine care, so that only 13% of those with Stage 
3b CKD could have a risk calculated. However, 
performance was a little better. Nevertheless, even 
the best performing of the Tangri models showed 
better discrimination amongst those with Stage 
4 CKD than Stage 3 CKD where the main clinical 
challenge remains.52
Table 1 continued.
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WHERE NEXT?
Thus, the models currently available, although 
demonstrated to be useable, are limited by a 
number of issues and flaws and so need further 
work. Reporting and testing of model performance 
was inconsistent, and while standard, basic tests 
of internal validity of the models tended to show 
promise, more transparent testing on external 
validation cohorts reporting sensitivity, specificity, 
false-positives, and false-negatives would be 
helpful in assessment of clinical utility, particularly 
using the suggested thresholds for identifying 
high-risk individuals.
Models that are practical to use in ‘real-life’ with 
real-life data such as the Tangri model should be 
given priority, and model refinement should ensure 
practical real-life useability. Models need to be 
judged in terms of the added value for care and 
service planning over the current use of referral 
guidelines based on eGFR and proteinuria.53 The 
addition of novel biological markers has, thus 
In our local cohort with CKD, using an RRT risk of >5% at 5 years as high-risk, the Tangri 3 and 4 
variable models performed as below:
CKD stage 
Number of patients with CKD
Number start RRT at 5 years
Missed RRT cases
Number high-risk
Sensitivity
Specificity 
3 variable model
3b
4,951
41
2 (5%)
2053
0.95
0.59
4
1,246
89
0 (0%)
1246
1.00
0.00
3b
650
14
2 (15%)
15
0.86
0.83
4
153
16
0 (0%)
125
1.00
0.20
4 variable model
Figure 2: Practical example of prediction model performance not illustrated using discrimination, 
calibration, and model fit indices.  
CKD: chronic kidney disease; RRT: renal replacement therapy.
Description How usually measured/reported
Discrimination Whether the model assigns a higher 
probability to individuals who have 
the outcome of interest versus 
those who do not.
Area under the receiver operating charac-
teristic (ROC) curve, or c-statistic.
0.50 is no better than chance.
0.70-0.80 good.
>0.80 excellent.
Calibration How well the predictions equate to 
actual outcome.
Calibration plots; variants on the Hosmer-
Lemeshow χ2 statistic, rank into deciles of 
predicted risk, then compare the expected 
and observed frequency of the outcome in 
each decile. If very different then not good 
calibration.
Goodness of fit How well the model fits the data 
concerned.
Akaike or Bayes information criterion, the 
lower the value the better fit of the model.
Reclassification How a newer (or more complex) 
model improves the reclassification 
of individuals – those with the event 
to a higher predicted risk and those 
without the event to a lower pre-
dicted risk.
Net reclassification improvement or inte-
grated discrimination improvement. If the 
direction of the reclassification is correct – 
those with events to higher risk, those with 
no events to lower risk, then the newer (or 
more complex) model is better.
Table 2: Common and expected indices for the reporting of prediction model performance.
 NEPHROLOGY  •  July 2014   EMJ  EUROPEAN MEDICAL JOURNAL  NEPHROLOGY  •  July 2014  EMJ  EUROPEAN MEDICAL JOURNAL 74 75
far, provided limited improvement in model 
performace and has restricted immediate clinical 
implications if testing for such markers is not in 
widespread clinical use. Greater gains for model 
refinement  might come from taking into account 
the type of information used in clinical practice to 
assess long term risks: rate and pattern of kidney 
function decline, comorbidity, and underlying renal 
pathology, for example.
Model performance has not been explored in 
depth in older age populations. Experience from 
the cardiovascular literature suggests that model 
performance may not be as good in the elderly.25,26 
In this age group, issues of competing risks from 
other morbidities and death become increasingly 
important. Further external validation of refined 
models in community settings such as primary care 
is required prior to any use in this context. Once 
these models have been refined, good quality 
randomised controlled trials of their introduction 
should be run to demonstrate any improvement in 
care and outcome delivery and absence of harm. 
This would then facilitate the introduction of 
stratified renal medicine appropriate to the risk 
profile of individuals concerned. Referral and 
intensive management with optimal implementation 
of current treatment guidelines could then be 
focused to those with the greatest opportunity 
to benefit. Health economic evaluation of the 
cost-effectiveness of different models of care 
delivery, based on stratification using prediction 
models, will be needed to support service 
planning, but the opportunity to reduce the need 
for referral to specialist services and frequency 
of follow-up has significant potential benefits for 
patients and health services.54
CONCLUSION
With the introduction of the KDOQI CKD 
guidelines, CKD is being identified more commonly, 
particularly in the elderly where milder renal 
impairment is predominant. The outcomes for those 
with CKD are poor – mortality, initiation of RRT, and 
progressive deterioration in kidney function, with its 
associated complications. In young CKD patients, 
the risk of poor outcome is high and the social 
cost substantial, but the actual numbers of 
patients affected is relatively small. In the elderly, 
the risk of a poor outcome is substantially lower, 
but due to the high prevalence of CKD the actual 
number of poor outcomes attributable to CKD 
is higher. Since >50% of those over the age of 
70 years have CKD, prediction models to stratify 
care by risk group, focusing on intervention, and 
delivering different models of care based on risk, 
have great potential particularly at a population 
level. Risk prediction models in CKD have been 
developed and show promise but, thus far, have 
limitations – clinical performance is not fully 
reported and external validation is rare. The 
clinical utility of these models lies, for example, 
in the ability to explore timing of dialysis access 
placement, but also requires further research. The 
introduction of such models has great potential to 
deliver appropriate stratified medical care, but this 
should be after appropriate randomised controlled 
trials of effect.
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